N-methyl piperazine compounds having dopamine receptor affinity
AssigneeAllelix Biopharmaceuticals Inc.
InventorsJian-Min Fu, Sumanas Rakhit
Life of this patent
Estimating the term…
Abstract
Described herein are D4 receptor-selective compounds of the general formula: ##STR1## wherein X.sub.1 is selected from CH.sub.2, NH, O and S; X.sub.2 - - is selected from CH.dbd., CH.sub.2 13 , and N.dbd.; R.sub.1 to R.sub.8 are each independently selected from H, C.sub.1-4 alkyl, halo, cyano, nitro and halo-substituted C.sub.1-4 alkyl and acid addition salts, solvates and hydrates thereof. Their use as ligands for dopamine receptor identification and in a drug screening program, and as pharmaceuticals to treat indications in which the D4 receptor is implicated, such as schizophrenia, is also described.
Claims9
A compound of Formula I ##STR8## wherein X.sub.1 is NH;
- X.sub.2 - - is N.dbd.;
- R.sub.1 to R.sub.4 to R.sub.8 are H and R.sub.5 is Cl, and
- wherein said compound is 4-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzob,e!1,4!diazepine.
A method for the treatment of a condition mediated by the D4 receptor, comprising the step of administering to a mammal in need of such treatment a composition according to claim 5.
Dependencies are inferred from the claim text.